Medical Device Manufacturing Leader Acquires Small Microinjection Molding Company

On June 5, American medical device manufacturing giant Cordica Medical announced the acquisition of California-based micro-molding company RapidWerks.

The transaction amount was not disclosed, but the consideration would not be high, because this company has, at most, a little over ten people, one core piece of equipment, several sets of molds, and a group of seasoned technicians who can master micron-level tolerances, and that’s about it.

But don't be fooled by the word "micro." The real prize in this deal is that fully automatic micro injection molding machine from Europe.

Not an ordinary BOY babyplast small machine, but a production-grade system that only a very small number of manufacturers in the world can reliably master. It can drive single-shot injection weight down to just a few tenths of a gram, lock tolerances into the micron range, and run continuously with consistent parts that do not drift. The rarity of this capability is far greater than RapidWerks’ revenue figure itself.

RapidWerks’ customers span orthopedics, cardiovascular, neuroscience, and pharmaceuticals, and they handle jobs where the parts are extremely small, the tolerances are extremely tight, and the materials are extremely finicky—PEEK, bioresorbable polymers, and the like. One slight misstep, and the part is scrap. The number of companies in the U.S. that can take on this kind of work can be counted on two hands.

Then why doesn’t Cordica just buy the equipment and hire people itself?

What it needs is not just the ability to do it, but a process package that has already been validated, along with customer channels and a quality system. RapidWerks comes with an ISO 13485 foundation and established customer relationships; once it is integrated into Cordica’s global manufacturing network of 19 U.S. plants plus facilities in Mexico and Singapore, it can take on larger orders the very next day.

This is the logic of acquisitions: using capital to buy time, and mergers to raise the barrier to entry.

Putting this in the context of Cordica’s moves over the past year makes the picture even clearer: first, it acquired the device CDMO company TAG3 Engineering, bringing product development and engineering in-house; then it took over Duke Emperial, filling the gap in catheter tubing extrusion; now, with the addition of RapidWerks’ micro-injection molding capabilities, the company can run the entire process—from concept design to tubing/catheters, precision micro-molded components, and mass-production assembly—within its own walls.

CEO Marshall White put it plainly: “Micro injection molding is a must-have in our technology roadmap. Once we bring it in-house, customers will be working with a single partner that takes full responsibility from start to finish—concept designs go in, compliant mass-produced products come out.”

Cordica doesn’t want to be the biggest; it wants to be the hardest to replace. It relies not on a single breakout technology, but on piecing together the most difficult processes scattered across the supply chain into a turnkey moat that others cannot copy. The European machine in this ten-person workshop is the latest piece to be added.